Alternative Name(s): Human Epidermal Growth Factor Receptor 2, ERBB2, NEU
Test Description
Overexpression of HER2 has been reported in approximately 20% of early-stage invasive breast cancer. The phosphorylation of HER2 may be biologically relevant and reflects the functional activity of the receptor.